This study aimed to evaluate the effects of Nigella sativa oil on serum level of systemic inflammation, oxidative stress, fasting blood glucose (FBG), and lipid profile in patients with type 2 diabetes mellitus (T2DM). This double-blind randomized clinical trial study was based on 50 patients with T2DM. Patients were allocated randomly to either N. sativa oil or placebo groups. The intervention group received 1,000 mg N. sativa oil as two capsules, daily for 8 weeks, whereas the placebo group received a corresponding placebo. At baseline and the end of the study, 5 ml blood was collected from each patient after 14-hour fasting for measuring serum C-reactive protein (hs-CRP), malondialdehyde (MDA), FBS, and lipid profile. Analyses covariance was performed to compare investigated parameters between two groups, controlled for relevant covariates. Using N. sativa supplement was significantly associated with decrease in FBS (p < .001), triglyceride (p < .001), total cholesterol (p < .001), low-density lipoprotein cholesterol (p < .001), serum hs-CRP, MDA (p < .001) and increase in serum level of high-density lipoprotein cholesterol (p < .001) in intervention group compared with placebo group. Nigella sativa oil supplement has cardiovascular protective effects in patients with T2DM, by improving the lipid profile and glycemia, by reducing the C-reactive protein level and the lipid peroxidation.
Introduction:With regard to the relationship between inflammation and insulin resistance and due to the lack of researches conducted about the effect of synbiotics on inflammatory markers in diabetes patients, this study was designed to investigate the effect of these markers.Methods:A double-blind, placebo-controlled trial was conducted among 44 type 2 diabetes patients. They were randomized to symbiotic or placebo group. Patients in the symbiotic group received one symbiotic tablet daily for 8 weeks whereas the placebo group received 1 placebo tablet. The hs-CRP concentration, TNF-α and IL-6 were measured by using ELISA kits. The dietary intakes of patients were assessed at the first and the end of the study and analyzed by Nutritionist IV. Data were analyzed by using SPSS 16.0 via paired and independent t- test.Results:Anthropometric and dietary data were not significantly different between the two groups at the first and the end of the study. The serum concentrations of hs-CRP, IL-6 and TNF-α decreased significantly in the symbiotic group at the end of week 8 compared to baseline (p<0.05). Also, no significant changes were seen in the placebo group (p>0.05). The reduction in inflammatory markers in the symbiotic group were significant in compared to the placebo group (P<0.05).Conclusions:Symbiotic supplementation can reduce serum hs-CRP, IL-6 and TNF-α concentrations, a risk factor for cardiovascular diseases.
Introduction: Among the most important risk factors for cardiovascular disease in hemodialysis patients are high concentrations of serum inflammation markers, lipid profiles, and oxidative stress. The present study aimed to investigate the effects of a synbiotic supplement on serum systemic inflammation, oxidative stress markers, and lipid profile in hemodialysis patients. Methods: Fifty hemodialysis patients were randomly allocated to synbiotic and placebo groups. The synbiotic group received 2 tablets per day of a synbiotic supplement (100 mg) Lactobacillus coagulans and fructo‐oligosaccharides for 8 weeks; whereas the placebo group received a similar appearing placebo. At the beginning and end of the study, 5 mL blood was taken after 12–14 hours of fasting. Findings: Mean values of serum C‐reactive protein (hs‐CRP) and malondialdehyde (MDA) significantly decreased in the synbiotic group at the end compared to the beginning of the study (P = 0.01). This reduction was significant in comparison with changes in the placebo group (P = 0.01). The synbiotic supplement also reduced serum total cholesterol (P = 0.001) and low‐density lipoprotein cholesterol (LDL‐c; P = 0.001) compared to the placebo group. Discussion: The synbiotic supplement used improves serum hs‐CRP and MDA, total cholesterol and LDL‐c in hemodialysis patients, which are known risk factors for cardiovascular disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.